Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 116
Selected: 0
NCT IDTitle
NCT00062868LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
NCT01570283ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
NCT00058617Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL
NCT03294954GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
NCT03192462TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
NCT00881920Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
NCT04099797C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
NCT01109095CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
NCT018226523rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
NCT05134740(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
NCT02065362TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC
NCT00058799Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
NCT02291848Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
NCT06198296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
NCT00078546EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
NCT02973113Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
NCT00953420Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
NCT03478215Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
NCT01205334Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
NCT00056966Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
NCT01447056Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
NCT04377932Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
NCT01192464EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
NCT01945619Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
NCT00082225LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)
NCT00902044Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
NCT00579111Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
NCT01713439Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL
NCT00078533Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant
NCT00058578Stem Cell Transplant to Treat Patients With Systemic Sclerosis
NCT01247701Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies
NCT02905188Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
NCT02108522Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
NCT00368082Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
NCT02932956Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
NCT00703222A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells
NCT00458679Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
NCT07197749Vitamin C With Steroids for Gastrointestinal GVHD
NCT07211737NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
NCT01774097Patients With Intermittent Claudication Injected With ALDH Bright Cells
NCT01853631Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
NCT00586274Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
NCT00516087LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
NCT00058786Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells
NCT00040469Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
NCT02475707Administration of Donor MultiTAA-Specific T Cells for ALL
NCT02287311Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
NCT05236764Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
NCT00586391CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL